Bambec (bambuterol). Oral solution and tablets for children. A monograph 1997, ISBN 1859390633.
Bone MF, Banham SW, Joshi RC, et al. Bambuterol and theophylline: differences in efficacy, tolerability in the treatment of chronic asthma. Eur Respir J 1995; 8 (Suppl.19): 72S.
Crompton GK, Ayres J, Basran G, et al. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. Am J Respir Crit Care Med 1999; 159: 824-8.
D'Alonzo GE, Smolensky MH, Feldman S, et al. Bambuterol in the treatment of asthma - a placebo-controlled comparison of once-daily morning vs. evening administration. Chest 1995; 107: 406-12.
Fleetham J, Grossman R, Knight A, et al. Bambuterol reduces the diurnal variation of peak expiratory flow rates in asthmatic patients. Eur Respir J 1991; 4 (Suppl.14): 480S.
Gunn SD, Ayres JG, McConchie SM. Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuteroltablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group. Eur J Clin Pharmacol 1995; 48: 23-8.
Knight A, Aoki F, Grossman R, et al. Bambuterol: a long-acting beta2-agonist.A dose finding study in elderly COPD patients. Eur Respir J 1990; 3 (Suppl.10): 321s.
Kuusela A-L, Marenk M, Sandahl G, et al. A comparative study with bambuterol oral solution once daily and terbutaline oral solution three times daily in 2-5 year old children with asthma. Eur Respir J 1997; 10 (Suppl. 25): 219S-20S.
McDonald CF, Pierce RJ, Thompson PJ, et al. Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstruction. J Asthma 1997; 34: 53-9.
Persson G, Baas A, Knight A, et al. One month treatment with the once daily oral beta 2-agonist bambuterol in asthmatic patients. Eur Respir J 1995; 8 (1): 34-9.
Persson G, Pahlm O, Gnosspelius Y. Oral bambuterol versus terbutaline in patients with asthma. Curr Ther Res 1995; 56: 457-65.
Petrie GR, Chookang JY, Hassan WU, et al. Bambuterol: effective in nocturnal asthma. Respir Med 1993; 87: 581-5.
Rosenborg J, Nyberg L. Stereoselective pharmacokinetics of terbutaline and its prodrug bambuterol. Proceeding of Second Jerusalem Conference on Pharmaceutical Sciences and Clinical Pharmacology, Jerusalem, Israel, May 24-29, 1992: p30.
Sitar DS, Warren CP, Aoki FY. Pharmacokinetics and pharmacodynamics of bambuterol, a long-acting bronchodilator pro-drug of terbutaline, in young and elderly patients with asthma. Clin Pharmacol Their 1992; 52: 297-306.
Wallaert B, Brun P, Ostinelli J, et al. A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms. Respir Med 1999; 93 (1): 33-8.
van Harreveld AJ, Peake MD, Murciano D, et al. A 12 month safety study of bambuterol, a new once daily beta2-agonist, in patients with chronic obstructive airways disease (COAD). Eur Respir J 1990; 3 (Suppl.10): 114S.
Wempe JB, Tammeling EP, Postma DS, et al. Effects of budesonide and bambuterol on circadian variation of airway responsiveness andnocturnal symptoms of asthma. J Allergy Clin Immunol 1992; 90: 349-57. |
